Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is the gold standard therapy for myopic choroidal neovascularization (CNV), as well as for neovascular age-related macular degeneration (AMD) and diabetic macular edema [1]. This evidence concerns the gene VEGFA and choroidal neovascularization.